Guidance on the use of imatinib for chronic myeloid leukaemia
National Institute for Clinical Excellence
Record ID 32003001211
English
Authors' objectives:
To provide guidance on the use of imatinib for chronic myeloid leukaemia. This guidance replaces Technology Appraisal Guidance No. 50 issued in October 2002.
Authors' recommendations:
Guidance:
1.1 Imatinib is recommended as first-line treatment for people with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in the chronic phase.
1.2 Imatinib is recommended as an option for the treatment of people with Philadelphia-chromosome-positive CML who initially present in the accelerated phase or with blast crisis. Additionally, imatinib is recommended as an option for people who present in the chronic phase and then progress to the accelerated phase or blast crisis if they have not received imatinib previously.
1.3 There is currently no evidence on clinical and cost effectiveness on which to base guidance on the continued use of imatinib that has been initiated in the chronic phase of CML but has failed to stop disease progression to either the accelerated phase or blast crisis. Therefore, under these circumstances the use of imatinib is recommended only in the context of further clinical study. The data for this study should be collected systematically to allow aggregation and analysis at a national level in order to inform the appraisal review.
1.4 For people in chronic-phase CML who are currently receiving interferon alpha (IFN-alpha) as first-line treatment, the decision about whether to change to imatinib should be informed by the response of the disease to current treatment and by the tolerance of the person to IFN-alpha. This decision should be made after informed discussion between the person with CML and the clinician responsible for treatment, taking full account of the evidence on the risks and benefits of imatinib and the wishes of the person.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=89859
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.